Tirzepatide
In stockLY329817639-residue lipidated peptide with a C20 fatty diacid chain that is an agonist at both the GIP and GLP-1 receptors. Researchers study its dual-receptor signalling and biased agonism.
Supplied as a single-chamber lyophilized vial with a colour-coded cap (Weight Regulation).
Research literature, not dosing or treatment instructions.
- A pharmacology paper compared tirzepatide's potency and signalling at the GIP and GLP-1 receptors and describes it as an imbalanced and biased agonist. (PMID 32730231)
- A mouse study measured amino-acid profiles in brown adipose tissue after tirzepatide exposure. (PMID 35921984)
Add the solvent slowly along the vial wall; swirl gently, never shake. Allow to dissolve fully. Six-step guide with photos →
Concentration calculator only. Enter the mass being calculated; blend components are not added automatically. Products are for in-vitro research.
Refer to the product label and supplier documentation for storage conditions. Lot-specific storage and expiry information is not available here.
Each certificate is published with its lot number.
Questions about Tirzepatide
How much published research is there on Tirzepatide?
The research library's PubMed search for Tirzepatide returned 157 records on 5 October 2026, 51 of them reviews. The library lists 2 studies chosen for what they measured. ClinicalTrials.gov lists 296 registered studies naming Tirzepatide (checked 5 October 2026).
Is Tirzepatide an approved medicine?
Medicinal products containing Tirzepatide appear in Drugs@FDA, and the research material we supply is not one of them. Drugs@FDA lists 2 applications naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them. Medicinal products containing tirzepatide are authorised by the US FDA, the European Commission and the MHRA. The EMA and the Heads of Medicines Agencies warned on 3 September 2025 about illegal medicines marketed as GLP-1 receptor agonists, naming tirzepatide. It is supplied for in-vitro laboratory research only, not for human or veterinary use.
Is the research material the same as the authorised medicine?
No. Medicinal products containing tirzepatide are authorised by regulators, and the research material supplied here is not one of them. It is supplied for in-vitro research only.
Why does the literature list show no clinical papers?
Clinical papers on tirzepatide state clinical outcomes in their titles and endpoints, so the research library lists only chemistry and pharmacology papers.
How does Tirzepatide differ from Semaglutide?
Semaglutide is a lipidated GLP-1 analogue acting at the GLP-1 receptor. Tirzepatide is a larger lipidated peptide acting at both the GIP and GLP-1 receptors. The comparison covers chemistry, receptor targets and regulatory position only.
How does Tirzepatide differ from Retatrutide?
Tirzepatide acts at the GIP and GLP-1 receptors. Retatrutide adds the glucagon receptor as a third target. Both are 39-residue lipidated peptides. Tirzepatide is an authorised medicine in the US, EU and UK; retatrutide is investigational.
How is the identity of Tirzepatide confirmed on a certificate?
A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 4813.5 Da listed on this page. The research library's guide to reading a certificate explains each field.
Is this product for human use?
No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.
Where can I find shipping information?
Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.
Often studied with
For research use only. Not for human or veterinary use.
What is Tirzepatide?
Tirzepatide is a 39-residue lipidated peptide with a C20 fatty diacid chain that acts as an agonist at both the GIP and GLP-1 receptors. The research material is not the authorised medicine. We supply Tirzepatide as a lyophilized vial for in-vitro laboratory research only.
What are the chemical identifiers of Tirzepatide?
Tirzepatide has the molecular formula C225H348N48O68, an average molecular weight of 4813.5 Da and CAS number 2023788-19-2.
Chemistry checked against PubChem (CID 166567236), 5 October 2026; full chemistry record in the research library.
What does published research on Tirzepatide cover?
A PubMed search for Tirzepatide returned 157 records on 5 October 2026, 51 of them reviews. Our research library lists 2 of these studies, chosen for what they measured.
- A pharmacology paper compared tirzepatide's potency and signalling at the GIP and GLP-1 receptors and describes it as an imbalanced and biased agonist. (Willard et al., JCI Insight, 2020; PMID 32730231)
- A mouse study measured amino-acid profiles in brown adipose tissue after tirzepatide exposure. (Samms et al., Mol Metab, 2022; PMID 35921984)
Mechanism, every cited study and the regulator records are on the Tirzepatide page of the research library. Papers are listed by what they measured, not as evidence of any use.
How is Tirzepatide supplied and stored?
Tirzepatide is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.
What is the regulatory status of Tirzepatide?
Drugs@FDA lists 2 applications naming this active ingredient, marketing status as listed: Prescription (checked 5 October 2026). Those are medicinal products. The research material we supply is not one of them.
Medicinal products containing tirzepatide are authorised by the US FDA, the European Commission and the MHRA. The EMA and the Heads of Medicines Agencies warned on 3 September 2025 about illegal medicines marketed as GLP-1 receptor agonists, naming tirzepatide.
A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Which related research pages and compounds are listed?
- Tirzepatide: chemistry, literature and regulatory status
- Tirzepatide compared with Semaglutide
- Tirzepatide compared with Retatrutide
- Incretin and glucagon receptors
- How to read a certificate of analysis
Related compounds in the catalog: